A new experimental triple action weight loss drug is associated with weight loss of up to 25% in individuals with obesity and type 2 diabetes, a large phase 3 clinical trial has reported. tinyurl.com/2udhmudh
doctors.net.uk
Triple action weight loss jab shows significant results in large international trial
A new experimental triple action weight loss drug is associated with weight loss of up to 25% in individuals with obesity and type 2 diabetes, a large phase 3 clinical trial has reported.